Bioo Scientific Create New Therapeutics Division

Bioo Scientific has launched a new division, Bioo Therapeutics, to leverage their drug delivery vehicles and experience in antibody and small molecule research. The company seeks to use it as a basis to develop therapeutic agents to combat cancer and other diseases.

Bioo Therapeutics flagship drug delivery technology is a patent pending antibody conjugation technology, which delivers small RNA drugs into specifically targeted cells or tissues.

The company said that the scientists at Bioo Scientific have made significant strides in developing and using antibody-based agents for the directed delivery of short interfering RNAs, by improving the loading capacity of antibody drug carriers and demonstrating their ability to deliver small RNAs into tumors generated from cells expressing the cell surface target.

The company added that the drugs or toxins can be attached to monoclonal antibodies which target a specific cell type forming monoclonal antibody conjugates. These monoclonal antibody conjugates are used as homing devices to deliver these substances directly into targeted cells.

Lance Ford, VP of research and business development at Bioo Scientific, said: “Bioo Therapeutics is actively seeking to partner with pharmaceutical companies or venture capitalists to make possible the therapeutic potential of this technology. This effort will advance targeted drug delivery which is vitally important for the development of new cures and treatments of cancer.”